Abiomed (ABMD) Stock Chart - Revenue & Earnings | Quarter Chart

Analyst Forecast

up to date

Select dashboard ▾ New custom dashboard

Income Statement▲

Revenue by Product

ProductService And Other

Revenue by Geography

UNITED STATESOutside the U.S MemberEuropeJAPANNon Us Non Europe Non JapanNon Us

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income

Margin (%)

Gross MarginOperating MarginNet Income Margin

Operating Expenses

Research And Development ExpensesSelling General And Administrative Expenses

EBITDA

EPS

EPSEPS Diluted

Revenue Variation (%)

Revenue Variation

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation

Revenue YoY Variation (%)

Revenue YoY Variation

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation

Price-to-Earning Ratio

P/E Ratio

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share

Cash Flow Statement▲

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue

Free Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow

Cash Flow to Debt Ratio

Cash At End Of Period

Balance Sheet▲

Current Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities

Quick Ratio

Total AssetsTotal Liabilities

Cash & Equivalents

Total Current AssetsTotal Non Current Assets

Total Assets

Total Current LiabilitiesTotal Non Current Liabilities

Total Liabilities

Total Stockholders Equity

Shareholders Equity

Asset Composition

Cash And Cash EquivalentsShort Term Investments

Debt Structure

Short Term Debt

Key Metrics▼

Abiomed (ABMD) Stock Chart - Revenue & Earnings | Quarter ChartView Abiomed (ABMD) quarterly revenue, earnings, DCF fair value, and financial charts. Free stock analysis on Quarter Chart.

Abiomed (ABMD) quarterly earnings & revenue

Abiomed (ABMD) reported revenue of $265.92M for Q2 2023, up 7.2% year-over-year, with net income of $106.13M and diluted EPS of $2.32.

Over the last four reported quarters, Abiomed generated $1.07B in revenue and $266.76M in net income.

Abiomed's next earnings report is scheduled for October 30, 2023.

Abiomed quarterly results

Fiscal quarter	Revenue	Revenue YoY	Net income	EPS (diluted)
Q2 2023	$265.92M	+7.2%	$106.13M	$2.32
Q1 2023	$277.15M	+9.7%	$54.55M	$1.19
Q4 2022	$269.85M	+11.9%	$60.33M	$1.31
Q3 2022	$261.18M	+12.7%	$45.75M	$1.00
Q2 2022	$248.14M	+18.3%	$56.95M	$1.24
Q1 2022	$252.59M	+53.2%	$-26.52M	$-0.59
Q4 2021	$241.25M	+16.7%	$56.86M	$1.24
Q3 2021	$231.66M	+4.5%	$61.87M	$1.35

📈 See Abiomed revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Abiomed (ABMD) — frequently asked questions

When does Abiomed (ABMD) report earnings next?

Abiomed is expected to report earnings on October 30, 2023.

What was ABMD's revenue last quarter?

Abiomed reported revenue of $265.92M in Q2 2023, up 7.2% from the same quarter a year earlier.

What was ABMD's EPS last quarter?

Abiomed reported diluted EPS of $2.32 in Q2 2023.

Is Abiomed profitable?

Abiomed is currently profitable, with $266.76M in net income over the last four reported quarters.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK)

Abiomed valuation & key metrics →